Carisma Therapeutics (CARM) Competitors $0.36 -0.03 (-7.09%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.38 +0.02 (+4.81%) As of 03/27/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. INCR, CUE, APLT, ANEB, PMVP, BDRX, STRO, INZY, VHAQ, and MGXShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include InterCure (INCR), Cue Biopharma (CUE), Applied Therapeutics (APLT), Anebulo Pharmaceuticals (ANEB), PMV Pharmaceuticals (PMVP), Biodexa Pharmaceuticals (BDRX), Sutro Biopharma (STRO), Inozyme Pharma (INZY), Viveon Health Acquisition (VHAQ), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. Carisma Therapeutics vs. InterCure Cue Biopharma Applied Therapeutics Anebulo Pharmaceuticals PMV Pharmaceuticals Biodexa Pharmaceuticals Sutro Biopharma Inozyme Pharma Viveon Health Acquisition Metagenomi Carisma Therapeutics (NASDAQ:CARM) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk. Does the MarketBeat Community favor CARM or INCR? Carisma Therapeutics received 14 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 77.27% of users gave Carisma Therapeutics an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% InterCureOutperform Votes3100.00% Underperform VotesNo Votes Do analysts recommend CARM or INCR? Carisma Therapeutics currently has a consensus price target of $4.94, indicating a potential upside of 1,280.66%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Carisma Therapeutics is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor CARM or INCR? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 2 articles in the media. Carisma Therapeutics' average media sentiment score of 0.94 beat InterCure's score of 0.93 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InterCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CARM or INCR? Carisma Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CARM or INCR? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is CARM or INCR more profitable? InterCure has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. InterCure's return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% InterCure N/A N/A N/A Which has better earnings & valuation, CARM or INCR? InterCure has higher revenue and earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$20.27M0.74-$86.88M-$1.56-0.23InterCure$272.67M0.23-$16.83MN/AN/A SummaryCarisma Therapeutics beats InterCure on 10 of the 16 factors compared between the two stocks. Remove Ads Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.94M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-0.237.2023.1419.03Price / Sales0.74226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book0.546.476.934.33Net Income-$86.88M$141.90M$3.20B$247.06M7 Day Performance-13.51%-3.20%-2.30%-0.37%1 Month Performance-10.77%-5.64%2.86%-3.85%1 Year Performance-84.24%-7.47%10.66%1.27% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.3359 of 5 stars$0.36-7.1%$4.94+1,280.7%-84.0%$14.94M$20.27M-0.2320INCRInterCure0.8372 of 5 stars$1.44-3.4%N/A-44.9%$65.63M$272.67M0.00350CUECue Biopharma4.4894 of 5 stars$1.03+4.6%$4.75+361.2%-45.7%$65.25M$9.53M-1.1460Positive NewsAPLTApplied Therapeutics4.2755 of 5 stars$0.56-2.3%$6.10+989.9%-92.1%$65.12M$-212,000.00-0.3530Upcoming EarningsPositive NewsANEBAnebulo Pharmaceuticals2.9872 of 5 stars$1.58-1.9%$8.00+406.3%-49.6%$64.91MN/A-5.644Short Interest ↓Positive NewsGap DownPMVPPMV Pharmaceuticals2.3005 of 5 stars$1.24-2.4%$5.50+343.5%-30.3%$64.40MN/A-1.2450BDRXBiodexa Pharmaceuticals0.414 of 5 stars$1.75-1.1%N/AN/A$63.95M$83,000.000.0020Short Interest ↑STROSutro Biopharma4.309 of 5 stars$0.77+0.4%$6.63+760.1%-85.0%$63.52M$62.04M-0.48240INZYInozyme Pharma3.7647 of 5 stars$1.01+3.7%$14.56+1,341.1%-86.5%$62.58MN/A-0.6550Positive NewsVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeMGXMetagenomi2.1019 of 5 stars$1.65+0.6%$14.40+772.7%-86.1%$61.68M$52.30M-0.63236Analyst RevisionNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies InterCure Alternatives Cue Biopharma Alternatives Applied Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Biodexa Pharmaceuticals Alternatives Sutro Biopharma Alternatives Inozyme Pharma Alternatives Viveon Health Acquisition Alternatives Metagenomi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CARM Stock Free CARM Stock Alerts